Patents Assigned to Diabetes Research Institute
  • Publication number: 20200325215
    Abstract: The invention includes the use of the HE/HE4a markers to assess ovarian cancer in a subject. Included also are compositions and methods of using HE/HE4a marker for diagnosis, grading and staging of ovarian cancers, determining prognosis and treatment effectiveness of a subject who has been diagnosed with ovarian cancer.
    Type: Application
    Filed: July 1, 2020
    Publication date: October 15, 2020
    Applicants: PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE, FUJIREBIO DIAGNOSTICS, INC.
    Inventors: Ingegerd HELLSTROM, Karl-Erik HELLSTROM, John RAYCRAFT, Christian FERMÉR, Eva RÖIJER
  • Publication number: 20190265151
    Abstract: Systems and methods that facilitate genetic research are described. The systems and methods can utilize (1) fluorescent dyes to sort tetrads from vegetative cells, dyads and dead cells; (2) natural genetic sequences to capture tetrad relationships of recombinant progeny; and (3) markers in parental organisms to identify genetic recombination events in genomic regions of interest.
    Type: Application
    Filed: July 14, 2017
    Publication date: August 29, 2019
    Applicant: PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE
    Inventors: Aimée M. Dudley, Gareth Cromie, Amy Sirr, Nikita Sakhanenko
  • Publication number: 20180057575
    Abstract: The invention includes the use of the HE/HE4a markers to assess ovarian cancer in a subject. Included also are compositions and methods of using HE/HE4a marker for diagnosis, grading and staging of ovarian cancers, determining prognosis and treatment effectiveness of a subject who has been diagnosed with ovarian cancer.
    Type: Application
    Filed: October 19, 2017
    Publication date: March 1, 2018
    Applicants: PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE, FUJIREBIO DIAGNOSTICS, INC.
    Inventors: Ingegerd HELLSTROM, Karl-Erik HELLSTROM, John RAYCRAFT, Christian FERMÉR, Eva RÖIJER
  • Patent number: 9822169
    Abstract: The invention includes the use of the HE/HE4a markers to assess ovarian cancer in a subject. Included also are compositions and methods of using HE/HE4a marker for diagnosis, grading and staging of ovarian cancers, determining prognosis and treatment effectiveness of a subject who has been diagnosed with ovarian cancer.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: November 21, 2017
    Assignees: PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE, FUJIREBIO DIAGNOSTICS, INC.
    Inventors: Ingegerd Hellstrom, Karl-Erik Hellstrom, John Raycraft, Christian Fermér, Eva Roijer
  • Patent number: 9750770
    Abstract: A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated. The graft consists of stem cells or progenitors that are admixed with biomaterials and, optionally, with cytokines and/or native epithelial-mesenchymal cells appropriate for the maturational lineage stage of the cells to be engrafted.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: September 5, 2017
    Assignees: The University of North Carolina at Chapel Hill, University of Miami-Diabetes Research Institute, Sapienza Università Di Roma
    Inventors: Lola M. Reid, Yunfang Wang, David A. Gerber, Giacomo Lanzoni, Luca Inverardi, Juan Dominguez-Bendala, Domenico Alvaro, Vincenzo Cardinale, Eugenio Gaudio, Guido Carpino
  • Publication number: 20140301985
    Abstract: A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated. The graft consists of stem cells or progenitors that are admixed with biomaterials and, optionally, with cytokines and/or native epithelial-mesenchymal cells appropriate for the maturational lineage stage of the cells to be engrafted.
    Type: Application
    Filed: March 12, 2014
    Publication date: October 9, 2014
    Applicants: University of North Carolina at Chapel Hill, Sapienza Università di Roma, Diabetes Research Institute
    Inventors: Lola M. REID, Yunfang WANG, David A. GERBER, Giacomo LANZONI, Luca INVERARDI, Juan DOMINGUEZ-BENDALA, Domenico ALVARO, Vincenzo CARDINALE, Eugenio GAUDIO, Guido CARPINO
  • Patent number: 8762070
    Abstract: A method, computer implemented method and associated apparatus for the management of diabetes comprises utilizing zone model predictive control (Zone-MPC) to control delivery of an insulin or insulin analog within a zone of desired values.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: June 24, 2014
    Assignees: Regents of the University of California, Sansum Diabetes Research Institute
    Inventors: Francis J. Doyle, III, Benyamin Grosman, Eyal Dassau, Lois Javanovic, Howard Zisser
  • Publication number: 20110208156
    Abstract: A method, computer implemented method and associated apparatus for the management of diabetes is provided.
    Type: Application
    Filed: February 11, 2011
    Publication date: August 25, 2011
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SANSUM DIABETES RESEARCH INSTITUTE
    Inventors: Francis J. Doyle, III, Benyamin Grosman, Eyal Dassau, Lois Javanovic, Howard Zisser
  • Patent number: 6630154
    Abstract: Disclosed and claimed are: a composition including at least one glycosaminoglycan, e.g., CIS, at least one perfluorinated substance and at least one alginate, e.g., sodium alginate, wherein: the at least one glycosaminoglycan and/or the perfluorinated substance and/or the alginate are cross-linked or polymerized, e.g., the alginate is cross-linked or polymerized, for instance by addition of an inorganic salt, such as a calcium salt; or the at least one glycosaminoglycan, the perfluorinated substance and the alginate are covalently bound, e.g., by means of a coupling reaction involving a linker molecule such as DVS; or the at least one glycosaminoglycan and/or the perfluorinated substance and/or the alginate are cross-linked or polymerized, e.g., the alginate is cross-linked or polymerized, for instance by addition of an inorganic salt, such as a calcium salt, and the at least one glycosaminoglycan and the alginate are covalently bound, e.g.
    Type: Grant
    Filed: January 4, 2000
    Date of Patent: October 7, 2003
    Assignees: Biomm, Inc., Diabetes Research Institute, University of Miami
    Inventors: Christopher Fraker, Luca Inverardi, Marcos Mares-Guia, Camillo Ricordi